乙酰半胱氨酸联合糖皮质激素对重度哮喘患者免疫功能及炎性因子的影响

鲍志坚

doi:10.16766/j.cnki.issn.1674-4152.2017.08.045

乙酰半胱氨酸联合糖皮质激素对重度哮喘患者免疫功能及炎性因子的影响

doi: 10.16766/j.cnki.issn.1674-4152.2017.08.045

鲍志坚

杭州市红十字会医院结核科, 浙江杭州 310003

基金项目:

浙江省卫计委项目（2015KYB312）

详细信息

中图分类号: R562.25;R977.11
计量
- 文章访问数: 80
- HTML全文浏览量: 22
- PDF下载量: 0
- 被引次数: 0
出版历程
- 收稿日期: 2016-12-08
- 网络出版日期: 2022-08-05

Influence of acetylcysteine combined glucocorticoids on immune function and inflammation of patients with severe asthma

BAO Zhijian

Department of Phthisiologia, Hangzhou Red Cross Hospital, Zhejiang 310003, China

摘要

摘要: 目的探讨乙酰半胱氨酸联合糖皮质激素治疗重度哮喘的临床效果及其对患者免疫功能及炎性因子的影响。方法以随机数字法将2015年8月—2016年4月杭州市红十字会医院收治的70例重度哮喘患者随机分为2组,每组35例。对照组给予糖皮质激素,观察组在此基础上加用乙酰半胱氨酸。治疗前后,检测患者免疫功能、炎性因子、呼吸道功能,并统计2组的治疗效果。结果治疗后,2组CD3、CD4、CD4/CD8、IgA、IgG和IgM水平均较前明显升高(P<0.05),CD8水平较前明显下降(P<0.05),且观察组CD3、CD4、CD4/CD8、IgA、IgG和IgM水平显著高于对照组(P<0.05),CD8水平显著低于对照组(P<0.05)。治疗后,2组TNF-α、hs-CRP和IL-8水平均较前明显下降(P<0.05),且观察组TNF-α、hs-CRP和IL-8水平显著低于对照组(P<0.05)。治疗后,2组PaO₂、FVC、FEV1、FEV1%、FEV1/FVC水平均明显升高(P<0.05),Pa CO₂明显下降(P<0.05),且观察组Pa O₂、FVC、FEV1、FEV1%、FEV1/FVC水平明显高于对照组(P<0.05),PaCO₂明显低于对照组(P<0.05)。治疗后,观察组治疗总有效率为91.3%,显著高于对照组的74.3%(P<0.05)。结论乙酰半胱氨酸联合糖皮质激素能显著改善重度哮喘患者的免疫功能、炎症、呼吸道功能,治疗效果满意。
- 乙酰半胱氨酸 /
- 糖皮质激素 /
- 重度哮喘
Abstract: Objective To investigate the clinical effects of acetylcysteine combined glucocorticoids on severe asthma and its influence on the immune function and inflammation, respiratory of patients. Methods Total 70 patients with severe asthma were randomly divided into two groups, with 35 cases in each group. The patients in the control group were given corticosteroids, while the patients in the observation group were given acetylcysteine combined glucocorticoids. Before and after the treatment, the immune function, inflammatory cytokines, respiratory function of the patients in the two groups were detected and the clinical efficacy was assessed. Results After the treatment, CD3, CD4, CD4/CD8, IgA, IgG and IgM levels of both groups were significantly increased (P < 0. 05), CD8 levels of both groups were significantly decreased (P <0. 05); CD3, CD4, CD4/CD8, IgA, IgG and IgM levels of the observation group were significantly higher than those of the control group (P < 0. 05), CD8 level of the observation group was significantly lower than that of the control group (P <0. 05). After the treatment, TNF-α, hs-CRP and IL-8 levels of both groups were significantly decreased (P < 0. 05), and TNF-α, hs-CRP and IL-8 levels of the observation group were significantly lower than those of the control group (P <0. 05). After the treatment, PaO₂, FVC, FEV1, FEV1%, FEV1/FVC of the two groups were significantly increased (P <0. 05), PaCO₂ levels of both groups were significantly decreased (P < 0. 05); PaO₂, FVC, FEV1, FEV1%, FEV1/FVC levels of the observation group were significantly higher than those of the control group (P < 0. 05), PaCO₂ level of the observation group was significantly lower than that of the control group (P < 0. 05). The total effective rate in the observation group was 91. 3%, which was significantly higher than that in the control group (74. 3%, P < 0. 05). Conclusion Acetylcysteine combined glucocorticoids could significantly improve immune function, inflammation, respiratory function of severe asthma patients, with satisfaction treatment.
- Acetylcysteine /
- Glucocorticoid /
- Severe asthma